TAG:
laboratory executive
Chiron Is Biotech Firm, Respected For Innovation
By Robert Michel | From the Volume V No. 13 – September 28, 1998 Issue
CEO SUMMARY: Chiron is respected for its leadership in branched DNA and viral load technologies. The company had high expectations for its diagnostics group, particularly after its purchase of Ciba Corning. But rapid consolidation of the diagnostics industry changed Chiron’s opportunity…
Curse Of Consolidation Plagues Health Providers
By Robert Michel | From the Volume V No. 13 – September 28, 1998 Issue
WITHOUT QUESTION, today’s healthcare world is dominated by a single obvious trend: consolidation. The consequences of consolidation affect every segment of healthcare in the United States. The commercial laboratory industry had the dubious distinction of being the first major segment of healthcare…
Unilab’s Bid To Buy Meris Will Shake Up California
By Robert Michel | From the Volume V No. 13 – September 28, 1998 Issue
CEO SUMMARY: More laboratory overcapacity may be removed from the California marketplace if Unilab purchases Meris Laboratories. Unilab’s offer to buy Meris must be cleared by the bankruptcy court and other bidders may surface during the coming weeks. These events are a reminder that fi…
Pathologists, Clin Labs, Pharmacogenomics & PPMs
By R. Lewis Dark | From the Volume V No. 12 – September 8, 1998 Issue
AT MY AGE, I AM LEARNING THAT PEOPLE TEND TO HOLD ONE OF TWO OPINIONS about me. It seems that I can frequently be considered a doddering old fool who is totally unhip (although I recall an even earlier generation calling it “unhep”). On the other hand, there are those who grant me great respect. …
Pharmacogenomics Is The Coming Wave
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
CEO SUMMARY: It may be gloom and doom today in the clinical laboratory industry, but long term prospects for diagnostic testing are brightening. Increased understanding of human genetics drives new discoveries about how and why the same drug affects individuals differently. Biotech compan…
Genetic Testing Almost Accented In Market Place
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
CEO SUMMARY: Advances in molecular and genetic science have generated the first generation of diagnostic assays for clinical use. As these assays reach the public, acceptance is not immediate. Obstacles are many: ethical, cultural, clinical, and economic. Oncormed’s experience during th…
DIANON Shoots At Urocor, Makes Unwelcome Offer
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
CEO SUMMARY: It pays to know your friends. Last month DIANON Systems announced an unsolicited offer to acquire UroCor. The offer, following months of ongoing discussions between the two companies, was clearly unwelcome at UroCor. Both companies are pushing hard to evolve disease managemen…
Veterans Administration Network Restructures Using Partnering, Telepathology
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
CEO SUMMARY: Economic pressures are forcing even the traditional and staid Veterans Administration to extensively reconfigure its laboratory services. At this year’s Executive War College in New Orleans, participants learned how one eight-hospi…
United Health’s Big Losses Derail Merger With Humana
By Robert Michel | From the Volume V No. 11 – August 17, 1998 Issue
CEO SUMMARY: Considered the darling of the managed care industry by investors, United Healthcare’s huge write-down makes it the latest healthcare behemoth to post an immense loss. Laboratory executives should see this as a sign that even big healthcare companies are struggling to develop fiscal sta…
“Corporatized” Healthcare Encountering Big Losses
By Robert Michel | From the Volume V No. 11 – August 17, 1998 Issue
CEO SUMMARY: When the clinical laboratory industry found itself losing hundreds of millions of dollars in recent years, few people imagined that billion-dollar HMO and PPM companies would soon experience similar losses. Current trends in the managed care marketplace indicate that problems…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized